Latin America Multiomics Market Size, Share & Trends Analysis Report By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics), By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria) and Forecast, 2026-2034

Latin America Multiomics Market Trends

AI-Enabled Integration and Higher-Throughput Molecular Profiling

Multi-layer biology is moving from disconnected analytical pipelines toward cloud-based, AI-assisted integration. Illumina Connected Multiomics entered full customer release in January 2026 after input from 40 early-access users, while its February 2026 v1.1 release added AI-assisted workflow suggestions. The shift addresses datasets spanning at least 4 major molecular layers—genomics, transcriptomics, proteomics and epigenomics—and reduces dependence on manually stitching together multiple specialist tools.

Single-cell and spatial technologies are simultaneously increasing experimental scale. Parse Biosciences' 2026 Evercode Whole Transcriptome v4 supports up to 5 million cells and 384 samples in one run, while Illumina's spatial transcriptomics roadmap targets millions of cells per slide, a 9-times larger capture area and 4-times greater resolution than referenced existing technologies. These capabilities strengthen demand from oncology, drug discovery, biomarker research and precision-medicine programs.

Latin America Multiomics Market Drivers

Expansion of High-Throughput Single-Cell and Integrated Molecular Workflows

Increasing experimental scale is accelerating adoption across pharmaceutical research and translational science. Evercode v4 can process up to 5 million cells and 384 samples per run, while QIAGEN reports Parse technologies are used by more than 3,000 customers. QIAsprint Connect can automate purification of up to 192 DNA or RNA samples per run. In proteomics, Bruker's timsUltra AIP delivers up to 35% more peptide and 20% more protein identifications, supporting higher-sensitivity single-cell workflows and increasing the quantity and complexity of biological information available for integrated analysis.

Latin America Multiomics Market Restraints

High Computational Complexity and Capital-Intensive Laboratory Infrastructure

Multi-layer analysis generates substantially larger computational requirements than isolated assays, creating pressure on bioinformatics expertise, storage and instrument budgets. Commercial platforms are responding with integrated software, yet adoption still requires sequencing, mass spectrometry, sample preparation and analysis infrastructure. Recent technology development illustrates the performance-cost tradeoff: spatial systems are targeting 9-times larger capture areas and 4-times greater resolution, while advanced proteomics systems report 20% more protein and 35% more peptide identifications. Such improvements increase analytical capacity but reinforce requirements for trained personnel and scalable computing.

Latin America Multiomics Market Opportunities

Population-Scale Precision Medicine and AI-Driven Biomarker Discovery

Population-scale research creates opportunities to connect sequencing with proteomic and clinical datasets. Thermo Fisher's 2026 collaboration with PRECISE-SG100K integrates population-scale proteomics with a major biobank initiative, while QIAGEN expects Parse to contribute approximately USD 40 million in 2026 sales following its approximately USD 225 million upfront acquisition, with potential milestone payments of up to USD 55 million. These investments demonstrate commercial momentum around scalable single-cell, AI and biomarker platforms that can be adapted to increasingly diverse population datasets.

Challenges in Latin America Multiomics Market

Standardization Across Increasingly Diverse Molecular Data Layers

Interoperability remains difficult as laboratories combine sequencing, single-cell, proteomics and metabolomics outputs generated at different scales. A single Evercode v4 workflow can cover 384 samples and 5 million cells, while biocrates assays acquired by Bruker cover more than 1,000 metabolites across over 40 metabolite classes. Harmonizing metadata, normalization, quality control and clinical interpretation across these highly dimensional datasets remains a central technical challenge despite rapid progress in cloud and AI-enabled analytical platforms.

Latin America Multiomics Market Segmentation

The industry is segmented by omics type, application, technology, offering and end user. Based on supplied numerical data, genomics represents approximately 34.9% of the USD 356.34 million omics total in 2026, followed by transcriptomics at approximately 19.8%. Proteomics accounts for approximately 12.3%, metabolomics 11.0%, epigenomics 9.1%, lipidomics 6.4% and microbiomics 6.4%.

By Omics Type

Genomics is the largest supplied category, increasing from USD 107.46 million in 2025 to USD 124.34 million in 2026 and USD 399.56 million by 2034 at 15.71% CAGR. Transcriptomics follows at USD 70.55 million in 2026 and USD 225.13 million by 2034, reflecting a 15.61% CAGR.

Lipidomics records the fastest supplied CAGR at 16.40%, advancing from USD 22.84 million in 2026 to USD 76.96 million by 2034. Microbiomics follows at 16.30%, while proteomics expands at 16.09% and metabolomics at 16.03%.

By Application

Applications comprise drug discovery and development, precision medicine and personalized therapy, biomarker identification, clinical diagnostics, agriculture and crop research, nutrigenomics, infectious-disease surveillance and systems-biology research. The input provides 8 application categories but no application-level revenue or CAGR figures; consequently, numerical subsegment values are not extrapolated or fabricated.

By Technology

Technology segmentation covers 6 categories: next-generation sequencing, mass spectrometry, microarrays, single-cell analysis, real-time PCR and integration platforms. NGS supports genomic and transcriptomic profiling, while mass spectrometry enables proteomic, metabolomic and lipidomic workflows. No technology-specific revenue or CAGR data were supplied, so quantitative leadership is not assigned.

By Offering

The offering landscape comprises 3 categories—software and services, instruments and consumables. Cloud analytics and AI are strengthening software integration, while sequencing and mass-spectrometry systems remain core laboratory infrastructure. The supplied tables contain no offering-level monetary values or CAGR, preventing unsupported quantitative ranking.

By End User

The 5 specified end-user groups are pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, hospitals and clinics, and government and public-health agencies. Their requirements range from discovery-scale screening to clinical diagnostics and surveillance; however, no end-user revenue or CAGR values were provided.

Latin America Multiomics Market Counties Outlook

The supplied regional instruction lists UAE, Turkey, Saudi Arabia, South Africa, Egypt and Nigeria, which are outside Latin America and have no values in the mandatory dataset. To preserve geographic and numerical integrity, the outlook therefore covers the five supplied Latin America countries rather than fabricating figures for unrelated geographies.

Brazil

Brazil leads at USD 137.91 million in 2026 versus USD 118.35 million in 2025 and is forecast at USD 468.93 million by 2034, registering 16.53% CAGR. It represents approximately 38.6% of the USD 357.38 million 2026 supplied country total.

Mexico

Mexico reaches USD 133.82 million in 2026 from USD 115.24 million in 2025 and is projected at USD 442.35 million by 2034. Its approximately 37.4% contribution in 2026 and 16.12% CAGR position it close behind Brazil.

Argentina

Argentina contributes approximately 10.0% of the supplied 2026 total, with revenue rising from USD 30.76 million in 2025 to USD 35.67 million in 2026. The country is projected to reach USD 116.62 million by 2034 at 15.96% CAGR.

Colombia and Chile

Colombia reaches USD 24.94 million in 2026 and USD 80.80 million by 2034 at 15.83% CAGR, while Chile advances from USD 25.04 million to USD 79.37 million at 15.51%. Together, the two countries contribute approximately 14.0% of the supplied 2026 country total.

Top players in Latin America Multiomics Market

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Bruker Corporation
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Pacific Biosciences
• Oxford Nanopore Technologies plc
• BGI Genomics
• Roche
• Waters Corporation

Top Two Companies

• Illumina, Inc.

A verified Latin America company-level percentage share is not available in the supplied dataset and therefore is not fabricated. Illumina maintains strong positioning through NGS, single-cell, spatial and integrated analytics. Connected Multiomics launched commercially in January 2026 after engagement with 40 early-access users, followed by AI-assisted functionality in v1.1. Its spatial roadmap targets a 9-times larger capture area and 4-times greater resolution, supporting integration across genomic, transcriptomic and epigenomic research.

• Thermo Fisher Scientific Inc.

No verified company-level Latin America percentage is supplied, so a numerical competitive share cannot responsibly be assigned. Thermo Fisher is positioned across mass spectrometry, proteomics, sequencing-related workflows and analytical software. At ASMS 2026, it introduced Orbitrap Tribrid Apex and Orbitrap Excedion systems alongside AI-enabled analytics and Olink proteomics, strengthening population-scale and drug-discovery workflows. Its PRECISE-SG100K collaboration further expands integration of proteomic, clinical and population datasets.

Recent Developments in Latin America Multiomics Market

• 2026: Illumina released Connected Multiomics, developed with input from 40 early-access users, followed by AI-assisted capabilities in version 1.1.
• 2026: Parse Biosciences, a QIAGEN company, introduced Evercode Whole Transcriptome v4, supporting up to 5 million cells and 384 samples in one run.
• 2026: Thermo Fisher unveiled Orbitrap Tribrid Apex and Orbitrap Excedion technologies for advanced proteomics and integrated biological analysis.
• 2025: QIAGEN agreed to acquire Parse Biosciences for approximately USD 225 million upfront plus potential milestones of up to USD 55 million; Parse was expected to contribute approximately USD 40 million in 2026 sales.
• 2025: Bruker acquired biocrates, adding standardized assays covering more than 1,000 metabolites across over 40 metabolite classes to its multiomics portfolio.

Research Methodology

The assessment applies a base year of 2025, current year of 2026 and forecast horizon of 2026–2034. Mandatory country and omics figures were taken directly from the supplied tables, while calculated percentages use those figures without altering source values. Public primary-company materials were used for technology, competitive and development context. Where application, technology, offering, end-user or company-level Latin America revenues were not supplied or independently verified, no unsupported numerical estimates were created. The resulting framework evaluates 5 supplied Latin America countries, 7 omics categories, 8 applications, 6 technologies, 3 offerings and 5 end-user categories.